I must tell you, I was really worried about this quarter. I thought it was going to be a lot less. Pearson added to my anxiety. If I had access to my broker last Thursday, I might have sold. I am really really glad I didn't panic.
I am concerned that they seem to be a little slow on getting new products issued. There "mystery" product originally for December, then February, is now to be introduced in April. The Par partnership drug isn't likely to be this summer (something I have been waiting for for nearly 2 years), and I felt was a 10 - 20 million dollar gross sale product per quarter. But they are growing nicely otherwise.
One other point of concern. They had said in the last quarter report that they had 14 products waiting fda approval (a number that has been rather consistent), and today said that it was only 12. But they haven't received any approvals since the last announcement. Have they abandoned any? Am I missing something? The gross amount has not changed (the targeted sales of the applications for approval - 1.5 billion) - maybe these were minor ones or consolidations??